1,721,561 research outputs found
Introduction of new atrial fibrillation ablation technology into clinical practice: the cart before the horse?
No full textJonathan M. Kalman and Prashanthan Sander
Blood pressure control in atrial fibrillation: one of many critical components in risk factor modification
No full textDennis H. Lau, Jeroen Hendriks, Jonathan M. Kalman, Prashanthan Sander
Response by Lau et al to letters regarding article, "modifiable risk factors and atrial fibrillation"
No full textAbstract not availableDennis H. Lau, Stanley Nattel, Jonathan M. Kalman, Prashanthan Sander
Device therapy for rate control: pacing, resynchronisation and AV node ablation
No full textAbstract not availableDennis H. Lau, Anand Thiyagarajah, Stephan Willems, Thomas Rostock, Dominik Linz, Martin K. Stiles, David Kaye, Jonathan M. Kalman, Prashanthan Sander
Absence of rotational activity detected using 2-dimensional phase mapping in the corresponding 3-dimensional phase maps in human persistent atrial fibrillation
No full textAbstract not availableBhupesh Pathik, Jonathan M. Kalman, Tomos Walters, Pawel Kuklik, Jichao Zhao, Andrew Madry, Prashanthan Sanders, Peter M. Kistler, Geoffrey Le
Primary prevention implantable cardioverter defibrillators in non-ischaemic cardiomyopathy: challenging the Australian heart failure guidelines
Get PDFAbstract not availableDennis H Lau, Jonathan M Kalman, Prashanthan Sander
Should we perform catheter ablation for asymptomatic atrial fibrillation?
No full textOriginally published July 31, 2017Since the original description of atrial fibrillation ablation, numerous studies have demonstrated the superiority of catheter ablation over pharmacological therapy for maintenance of sinus rhythm in patients with both paroxysmal and persistent atrial fibrillation. However, to date, no randomized studies have been powered to demonstrate a mortality or stroke reduction benefit of rhythm control with catheter ablation over a rate control strategy. The results of such ongoing studies are not expected until 2018 or 2019. Thus, the only indication for atrial fibrillation ablation in recent guidelines has been the presence of symptoms. However, up to 40% of an atrial fibrillation population may be asymptomatic. In 2017, in the absence of randomized studies, are there nevertheless data that support atrial fibrillation ablation in asymptomatic patients?Jonathan M. Kalman, Prashanthan Sanders, Raphael Rosso, Hugh Calkin
Going Beyond Counting First Authors in Author Co-citation Analysis
Get PDFThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Towards Improved Care of Postural Tachycardia Syndrome, Inappropriate Sinus Tachycardia and Vasovagal Syncope Patients: A Call to Action in Australia
No full textDennis H. Lau, Rajiv Mahajan, Geoffrey Lee, Jonathan M. Kalman, Prashanthan Sander
- …
